Returning investor PPD co-led a $40m round for the remote clinical trials service, while Novartis, Amgen, Sanofi and Alphabet also doubled down on their commitments.
US-based clinical trials platform operator Science 37 completed a $40m funding round yesterday co-led by contract research organisation PPD, venture capital firm Lux Capital and hedge fund Redmile Group.
Pharmaceutical firms Novartis, Amgen and Sanofi all participated in the round, the latter through its Sanofi Ventures unit, and they were joined by GV, an early-stage investment arm of internet technology group Alphabet.
Mubadala Ventures, the VC arm of United Arab Emirates’ sovereign wealth fund Mubadala, filled out the oversubscribed round…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
